Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases

Respiration

Volumn 77, Issue 1, 2009, Pages 3-17

  Ferrazza, A M ^a   Martolini, D ^a   Valli, G ^a   Palange, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Exercise testing, prognosis; Lung disease; Oxygen uptake; Time to exercise limitation; Ventilatory efficiency

Indexed keywords

CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; EXERCISE TOLERANCE; FUNCTIONAL ASSESSMENT; GOLD STANDARD; HUMAN; HYPERTRANSLUCENT LUNG; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EXERCISE; EXERCISE TEST; HUMANS; LUNG DISEASES; OXYGEN CONSUMPTION; PROGNOSIS; PULMONARY GAS EXCHANGE;

EID: 58249094963     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000186694     Document Type: Review

References (142)

1. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ: Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007;29:185-209.
2. Leidy NK, Wyrwich KW: Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD 2005;2:157-165.
3. O'Donnell DE, Chau LKL, Bertley JC, Webb KA: Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997;155:109-115.
4. Wasserman K, Whipp BJ, Koyan SN, Cleary MG: Effect of carotid body resection on ventilatory and acid-base control during exercise. J Appl Physiol 1975;39:354-358.
5. Killian KJ: Limitation to muscular activity in chronic obstructive pulmonary disease. Eur Respir J 2004;24:6-7.
6. Gandevia B, Hugh-Jones P: Terminology of measurements of ventilatory capacity. Thorax 1957;12:290-293.
7. Dillard TA, Piantadosi S, Rajagopal KR: Prediction of ventilation at maximal exercise in chronic airflow obstruction. Am Rev Respir Dis 1985;132:230-235.
8. Sue DY, Hansen JE: Normal values in adults during exercise testing. Clin Chest Med 1984;5:89-98.
9. Wasserman K, Hansen JE, Sue DY: Principles of Exercise Testing and Interpretation. Philadelphia, Lea & Febiger, 1994.
10. Jones NL: Clinical Exercise Testing, ed 3. Philadelphia, WB Saunders Co., 1988.
11. Hansen JE II: Respiratory abnormalities: exercise evaluation of the dyspnoeic patient; in Leff AR (ed): Cardiopulmonary Exercise Testing. New York, Grune & Stratton, 1986, pp 668-688.
12. Johnson BD, Weisman IM, Zeballos RJ, Beck KC: Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. Chest 1999;116:488-503.
13. Hansen JE, Sue DY, Wasserman K: Predicted values for clinical exercise testing. Am Rev Respir Dis 1984;129:S49-S55.
14. Whipp BJ, Wasserman K: Alveolar-arterial gas tension differences during graded exercise. J Appl Physiol 1969;27:361-365.
15. Badesch DB, Abman SH, Ahearn GS, et al: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
16. Mak VH, Bugler JR, Roberts CM, Spiro SG: Effect of arterial oxygen desaturation on six minute walk distance, perceived effort, and perceived breathlessness in patients with airflow limitation. Thorax 1993;48:33-38.
17. Poulain M, Durand F, Palomba B, et al: 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest 2003;123:1401-1407.
18. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-277.
19. Oga T, Nishimura K, Tsukino M, et al: The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests. Am J Respir Crit Care Med 2000;161:1897-1901.
20. Palange P, Crimi E, Pellegrino R, et al: Supplemental oxygen and heliox: 'new' tools for exercise training in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2005;11:145-148.
21. Wasserman K, Whipp BJ, Casaburi R: Respiratory control during exercise; in Fishman AP (ed): Handbook of Physiology, section 3, vol 3, part 2: The Respiratory System. Bethesda, American Physiological Society, 1986, pp 595-619.
22. Casaburi R, Porszasz J, Burns MR, et al: Physiologic benefits of exercise training in rehabilitation of severe COPD patients. Am J Respir Crit Care Med 1997;155:1541-1551.
23. Wasserman K, Hansen JE, Sue DY, Stringer W, Whipp BJ: Principles of Exercise Testing and Interpretation, ed 4. Philadelphia, Lea & Febiger, 2004.
24. Paterson DH, Cunningham DA: The gas transporting systems: limits and modifications with age and training. Can J Appl Physiol 1999;24:28-40.
25. Puente-Maestu L, Sanz ML, Sanz P, Ruiz de Ona JM, Rodriguez-Hermosa JL, Whipp BJ: Effects of two types of training on pulmonary and cardiac responses to moderate exercise in patients with COPD. Eur Respir J 2000;15:1026-1032.
26. Poole DC, Ward SA, Gardner GW, et al: Metabolic and respiratory profile of the upper limit for prolonged exercise in man. Ergonomics 1988;31:1265-1279.
27. Poole DC, Ward SA, Whipp BJ: The effects of training on the metabolic and respiratory profile of high-intensity cycle ergometer exercise. Eur J Appl Physiol 1990;59:421-429.
28. O'Donnell DE, Fluge T, Gerken F, et al: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840.
29. Somfay A, Porszasz J, Lee SM, et al: Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001;18:77-84.
30. Palange P, Valli G, Onorati P, et al: Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 2004;97:1637-1642.
31. Emtner M, Porszasz J, Burns M, et al: Benefits of supplemental oxygen in exercise training in non-hypoxemic COPD patients. Am J Respir Crit Care Med 2003;168:1034-1042.
32. O'Donnell DE, Webb KA: Exercise reconditioning in patients with chronic airflow limitation; in Torg JS, Shepherd RJ (eds): Current Therapy in Sports Medicine, ed 3. St. Louis, Mosby Year Book, 1995, pp 678-684.
33. O'Donnell DE, Webb KA: Exertional breathlessness in patients with chronic airflow limitation: the role of hyperinflation. Am Rev Respir Dis 1993;148:1351-1357.
34. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJM: Exercise capacity and ventilatory, circulatory and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992;146:935-940.
35. Hamilton AL, Killian KJ, Summers E, Jones NL: Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996;110:1255-1263.
36. Harms CA, Babcock MA, McClaran SR, et al: Respiratory muscle work compromises leg blood flow during maximal exercise. J Appl Physiol 1997;82:1573-1583.
37. Levison H, Cherniack RM: Ventilatory cost of exercise in chronic obstructive pulmonary disease. J Appl Physiol 1968;25:21-27.
38. Hyatt RE: Expiratory flow limitation. J Appl Physiol 1983;55:1-8.
39. O'Donnell DE, Webb KA: Exercise; in Calverley P, MacNee W, Rennard S, Pride N (eds): Chronic Obstructive Lung Disease, ed 2. London, Edward Arnold, 2003, pp 243-265.
40. Diaz O, Villafranco C, Ghezzo H, et al: Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000;16:269-275.
41. O'Donnell DE, Revill S, Webb KA: Dynamic hyperinflation and exercise intolerance in COPD. Am J Respir Crit Care Med 2001;164:770-777.
42. 2, maximum work rate, and walking distance in patients with emphysema. Chest 2003;123:1394-1400.
43. O'Donnell DE: Exercise limitation and clinical exercise testing in chronic obstructive pulmonary disease; in: Weisman IM, Zeballos RJ (eds): Clinical Exercise Testing. Basel, Karger, 2002, pp 138-158.
44. Oga T, Nissimura K, Tsukino M, Hajiro T, Ikeda A, Mishima M: Relationship between different indices of exercise capacity and clinical measures in patients with chronic obstructive pulmonary disease. Heart Lung 2002;31:374-381.
45. Potter WA, Olafsson S, Hyatt RE: Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease. J Clin Invest 1971;50:910-919.
46. Dodd DS, Brancatisano T, Engel LA: Chest wall mechanics during exercise in patients with severe chronic airway obstruction. Am Rev Respir Dis 1984;129:33-38.
47. Stubbing DG, Pengelly LD, Morse JLC, Jones NL: Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J Appl Physiol 1980;49:511-515.
48. Babb TG, Viggiano R, Hurley B, Staats B, Rodarte JR: Effect of mild-to-moderate airflow limitation on exercise capacity. J Appl Physiol 1991;70:223-230.
49. Yan S, Kaminski D, Sliwinski P: Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:55-59.
50. Pride NB, Macklem PT: Lung mechanics in disease; in Fishman AP (ed): Handbook of Physiology, section 3, vol. 3, part 2: The Respiratory System. Bethesda, American Physiological Society 1986, pp 659-692.
51. Younes M: Determinants of thoracic excursions during exercise; in Whipp BJ, Wasserman K (eds): Lung Biology in Health and Disease, vol 42: Exercise, Pulmonary Physiology and Pathophysiology. New York, Marcel Dekker, 1991, pp 1-65.
52. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
53. Vogiatzis I, Georgiadou O, Golemati S, et al: Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease. Thorax 2005;60:723-729.
54. O'Donnell DE, He Z, Lam M, Webb KA, Hamilton A: Reproducibility of measurements of inspiratory capacity, dyspnea intensity and exercise endurance in multicentre trials in COPD. Eur Respir J 2004;24(suppl 48):323s.
55. O'Donnell DE, Revill SM, Webb KA: Dynamic hyperinflaction and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-777.
56. Grimby G, Bunn J, Mead J: Relative contribution of rib cage and abdomen to ventilation during exercise. J Appl Physiol 1968;24:159-166.
57. Ward SA: Discriminating features of responses in cardiopulmonary exercise testing; in Ward SA, Palange P (eds): Clinical Exercise Testing. Eur Respir Mon 2007;40:36-68.
58. Barbera JA, Roca J, Ramirez J, Wagner PD, Usetti P, Rodriquez-Roisin R: Gas exchange during exercise in mild chronic obstructive pulmonary disease: correlation with lung structure. Am Rev Respir Dis 1991;144:520-525.
59. Dantzker DR, D'Alonzo GE: The effect of exercise on pulmonary gas exchange in patients with severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;134:1135-1139.
60. Hiraga T, Maekura R, Okuda Y, et al: Prognostic predictors for survival in patients with COPD using cardiopulmonary exercise testing. Clin Physiol Funct Imaging 2003;23:324-331.
61. Palange P, Forte S, Onorati P, Manfredi F, Serra P, Carlone S: Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J Appl Physiol 2000;88:1715-1720.
62. Turner SE, Eastwood PR, Cecins NM, Hillman DR, Jenkins SC: Physiologic responses to incremental and self-paced exercise in COPD: a comparison of three tests. Chest 2004;126:766-773.
63. Man WD, Soliman MG, Gearing J, et al: Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:562-567.
64. Gosselink R, Troosters R, Decramer M: Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996;153:976-980.
65. Palange P, Forte S, Onorati P, Paravati V, Manfredi F, Serra P, Carlone S: Effect of reduced body weight on muscle aerobic capacity in patients with COPD. Chest 1998;114:12-18.
66. Kelsen SG, Ference M, Kapoor S: Effects of prolonged undernutrition on structure and function of the diaphragm. J Appl Physiol 1985;58:1354-1359.
67. Gertz I, Hedenstierna G, Hellers G, Wahren J: Muscle metabolism in patients with chronic obstructive lung disease and acute respiratory failure. Clin Sci Mol Med 1977;52:395-403.
68. Nery LE, Wasserman K, Andrews JD, Huntsman DJ, Hansen JE, Whipp BJ: Ventilatory and gas exchange kinetics during exercise in chronic airway obstruction. J Appl Physiol 1982;53:1594-1602.
69. Palange P, Galassetti P, Mannix ET, Farber MO, Manfredi F, Serra P, Carlone S: Oxygen effect on O2 deficit and VO2 kinetics during exercise in obstructive pulmonary disease. J Appl Physiol 1995;78:2228-2234.
70. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T: Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167:544-549.
71. Schonhofer B, Dellweg D, Suchi S, Kohler D: Exercise endurance before and after long-term noninvasive ventilation in patients with chronic respiratory failure. Respiration 2008;75:296-303.
72. National Emphysema Treatment Trial Research Group: Cost effectiveness of lung volume reduction surgery for patients with severe emphysema. N Engl J Med 2003;348:2092-2102.
73. O'Donnell DE, Fitzpatrick MF: Physiology of interstitial lung disease; in Schwartz MI, King TE Jr (eds): Interstitial Lung Disease, ed 4. Hamilton, Decker, 2003, pp 54-74.
74. Widimsky J, Riedel M, Stonek V: Central hemodynamics during exercise in patients with restrictive pulmonary disease. Bull Eur Physiopathol Respir 1977;13:369-379.
75. Yernault JC, de Jonghe M, de Coster A, Englert M: Pulmonary mechanics in diffuse fibrosing alveolitis. Bull Eur Physiopathol Respir 1975;22:231-244.
76. Gibson GJ, Pride NB: Pulmonary mechanics in fibrosing alveolitis: the effects of lung shrinkage. Am Rev Respir Dis 1977;116:637-647.
77. Jones NL, Rebuck AS: Tidal volume during exercise in patients with diffuse fibrosing alveolitis. Bull Eur Physiopathol Respir 1979;15:321-328.
78. Marciniuk DD, Sridhar G, Clemens RE, Zintel TA, Gallagher CG: Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. J Appl Physiol 1994;77:963-973.
79. O'Donnell DE, Chau LKL, Webb KA: Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol 1998;84:2000-2009.
80. Keogh BA, Lakatos E, Price D, Crystal RG: Importance of the lower respiratory tract in oxygen transfer: exercise testing in patients with interstitial and destructive lung disease. Am Rev Respir Dis 1984;129:S76-S80.
81. Risk C, Epler GR, Gaensler EA: Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984;5:69-74.
82. Johnson RL Jr, Spice WS, Bishop JM, Forster RE: Pulmonary capillary blood volume, flow and diffusing capacity during exercise. J Appl Physiol 1960;15:893-902.
83. Agusti AGN, Roca J, Gea J, Wagner PD, Zaubet A, Rodriguez-Roisin R: Mechanisms of gas exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991;143:219-225.
84. CO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. Respir Physiol 1991;83:155-166.
85. Hamer J: Cause of low arterial oxygen saturation in pulmonary fibrosis. Thorax 1964;19:507-514.
86. Weitzenblum E, Ehrhart M, Rasaholinjanahary I, Hirth C: Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 1983;44:118-127.
87. Enson Y, Thomas HM, Bosken CH, et al: Pulmonary hypertension in interstitial lung disease: relation of vascular resistance to abnormal lung structure. Trans Assoc Am Physicians 1975;88:248-255.
88. McLees B, Fulmer J, Adair N, et al: Correlative studies of pulmonary hypertension in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1977;115:354A.
89. Jezek V, Michalnanik A, Fucik J, Ramaisl R: Long-term development of pulmonary arterial pressure in diffuse interstitial lung fibrosis. Prog Respir Res 1985;20:170-175.
90. Hawrylkiewicz I, Izdebska-Makosa Z, Grebska E, Zielinski J: Pulmonary haemodynamics at rest and on exercise in patients with idiopathic pulmonary fibrosis. Bull Eur Physiopathol Respir 1982;18:403-410.
91. Lupi-Herrera E, Seoane M, Verdejo J, et al: Hemodynamic effects of hydralazine in interstitial lung disease patients with cor pulmonale: immediate and short-term evaluation at rest and during exercise. Chest 1985;87:564-573.
92. Bush A, Busst CM: Cardiovascular function at rest and on exercise in patients with cryptogenic fibrosing alveolitis. Thorax 1988;43:276-283.
93. Sturani C, Papiris S, Galavotti V, Gunella G: Pulmonary vascular responsiveness at rest and during exercise in idiopathic pulmonary fibrosis: effects of oxygen and nifedipine. Respiration 1986;50:117-129.
94. Baughman PR, Gerson M, Bosken CH: Right and left ventricular function at rest and with exercise in patients with sarcoidosis. Chest 1984;85:301-306.
95. Eklund A, Broman L, Broman M, Holmgren A: V/Q and alveolar gas exchange in pulmonary sarcoidosis. Eur Respir J 1989;2:135-144.
96. Guttadauria M, Ellman H, Kaplan D: Progressive systemic sclerosis: pulmonary involvement. Clin Rheum Dis 1979;5:151-166.
97. Miki K, Maekura R, Hiraga T, et al: Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med 2003;97:482-490.
98. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM: Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-1181.
99. Markowitz DH, Systrom DM: Diagnosis of pulmonary vascular limit to exercise by cardiopulmonary exercise testing. J Heart Lung Transplant 2004;23:88-95.
100. Wensel R, Opitz CF, Anker SD, et al: Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319-324.
101. Sun XG, Hansen JR, Oudiz RJ, Wasserman K: Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001;104:429-435.
102. Systrom DM, Cockrill BA, Hales CA: Role of cardiopulmonary exercise testing in patients with pulmonary vascular disease; in Weisman IM, Zeballos RJ (eds): Clinical Exercise Testing. Basel, Karger, 2002, pp 200-204.
103. Deboeck G, Niset G, Lamotte M, Vachiery JL, Naeije R: Exercise testing in pulmonary arterial hypertension and in chronic heart failure. Eur Respir J 2004;23:747-751.
104. 2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest 2005;127:1637-1646.
105. Ting H, Sun XG, Chuang ML, Lewis DA, Hansen JE: A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertension. Chest 2001;119:824-832.
106. Aguggini G, Clement MG, Widdicombe JG: Lung reflexes affecting the larynx in the pig, and the effect of pulmonary microembolism. Q J Exp Physiol 1987;72:95-104.
107. Wasserman K, Hansen J, Sue DY, Casaburi R, Whipp B (eds): Principles of Exercise Testing and Interpretation, ed 3. Baltimore, Lippincott, Williams & Wilkins, 1999.
108. Valli G, Vizza CD, Onorati P, Badagliacca R, Ciuffa R, Poscia R, Brandimarte F, Fedele F, Serra P, Palange P: Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. Eur J Appl Physiol 2008;102:417-424.
109. Holverda S, Gan CT, Marcus JT, Postmus PE, Boonstra A, Vonk-Noordegraaf A: Impaired stroke volume response to exercise in pulmonary arterial hypertension. J Am Coll Cardiol 2006;47:1732-1733.
110. Schneiderman-Walker J, Pollock SL, Corey M, et al: A randomised controlled trial of a 3-year home exercise programme in cystic fibrosis. J Pediatr 2000;136:304-310.
111. Moorcroft AJ, Dodd ME, Morris J, Webb AK: Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial. Thorax 2004;59:1074-1080.
112. Godfrey S, Mearns M: Pulmonary function and response to exercise in cystic fibrosis. Arch Dis Child 1971;46:144-151.
113. Cerny FJ, Pullano TP, Cropp GJ: Cardiorespiratory adaptations to exercise in cystic fibrosis. Am Rev Respir Dis 1982;126:217-220.
114. Moorcroft AJ, Dodd ME, Webb AK: Long-term change in exercise capacity, body mass, and pulmonary function in adults with cystic fibrosis. Chest 1997;111:338-343.
115. Selvadurai HC, Allen J, Sachinwalla T, et al: Muscle function and resting energy expenditure in female athletes with cystic fibrosis. Am J Respir Crit Care Med 2003;66:1476-1480.
116. Moser C, Tirakitsoontorn P, Nussbaum E, Newcomb R, Cooper D: Muscle size and cardiorespiratory response to exercise in cystic fibrosis 2000. Am J Respir Crit Care Med 2000;162:1823-1827.
117. Shah AR, Gozal D, Keens TG: Determinants of aerobic and anaerobic exercise performance in cystic fibrosis. Am J Respir Crit Care Med 1988;157:1145-1150.
118. Klijn PH, van der Net J, Kimpen JL, Helders PJ, van der Ent CK: Longitudinal determinants of peak anaerobic performance in children with cystic fibrosis. Chest 2003;124:2215-2219.
119. Klijn PH, Terheggen-Lagro W, van der Ent CK, van der Net J, Kimpen JL, Helders PJ: Anaerobic exercise in pediatric cystic fibrosis. Pediatr Pulmonol 2003;36:223-229.
120. Marcotte JE, Grisdale RK, Levison H, Ceates AL, Canny GJ: Multiple factors limit exercise capacity in cystic fibrosis. Pediatr Pulmonol 1986;2:274-281.
121. Coates AL, Boyce P, Muller D, Mearns M, Godfrey S: The role of nutritional status, airway obstruction, hypoxia, and abnormalities in serum lipid composition in limiting exercise tolerance in children with cystic fibrosis. Acta Paediatr Scand 1980;69:353-358.
122. Lands LC, Heigenhauser GJ, Jones NL: Analysis of factors imiting maximal exercise performance in cystic fibrosis. Clin Sci 1991;83:391-397.
123. De Meer K, Gulmans VAM, van der Laag J: Peripheral muscle weakness and exercise capacity in children with cystic fibrosis. Am J Respir Crit Care Med 1999;159:748-754.
124. Thin AG, Dodd JD, Gallagher CG, et al: Effect of respiratory rate on airway dead space ventilation during exercise in cystic fibrosis. Respir Med 2004;98:1063-1070.
125. Hjeltnes N, Stanghelle JK, Skyberg D: Pulmonary function and oxygen uptake during exercise in 16-year-old boys with cystic fibrosis. Acta Paediatr Scand 1984;73:548-553.
126. Martin D, Day J, Ward G, Carter E, Chesrown S: Effects of breathing a normoxic helium mixture on exercise tolerance of patients with cystic fibrosis. Pediatr Pulmonol 1994;18:206-210.
127. McLoughlin P, McKeogh D, Byrne P, Finlay G, Hayes J, FitzGerald MX: Assessment of fitness in patients with cystic fibrosis and mild lung disease. Thorax 1997;52:425-430.
128. Nikolaizik WH, Knopfli B, Leister E, de Boer P, Sievers B, Schoni MH: The anaerobic threshold in cystic fibrosis: comparison of V-slope method, lactate turn points, and Conconi test. Pediatr Pulmonol 1998;25:147-153.
129. Lebecque P, Lapierre JG, Lamarre A, et al: Diffusion capacity and oxygen desaturation effects on exercise in patients with cystic fibrosis. Chest 1987;91:693-697.
130. Moorcroft AJ, Dodd ME, Morris J, Webb AK: Symptoms, lactate and exercise limitation at peak cycle ergometry in adults with cystic fibrosis. Eur Respir J 2005;25:1050-1056.
131. Marcotte JE, Canny GJ, Grisdale R, et al: Effects of nutritional status on exercise performance in advanced cystic fibrosis. Chest 1986;90:375-379.
132. Boas SR, Joswiak ML, Nixon PA, Fulton JA, Orenstein DM: Factors limiting anaerobic performance in adolescent males with cystic fibrosis. Med Sci Sports Exer 1996;28:291-298.
133. Boucher GP, Lands L, Hay JA, Hornby L: Activity levels and relationship to lung function and nutritional status in children with cystic fibrosis. Am J Phys Med Rehab 1997;76:311-315.
134. Nixon PA, Orenstein DM, Kelsey SF: Habitual activity in children and adolescents with cystic fibrosis. Med Sci Sports Exer 2001;33:30-35.
135. Kerem E, Reisman J, Corey M, Canny GJ, Levison H: Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-1191.
136. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998;158:335-339.
137. Augarten A, Akons H, Aviram M, et al: Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediat Transplant 2001;5:339-342.
138. Sharples L, Hathaway T, Dennis C, Caine N, Higenbottam T, Wallwork J: Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation. J Heart Lung Transplant 1993;12:669-674.
139. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF: The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992;327:1785-1788.
140. Stanghelle JK, Skyberg D, Haanaes OC: Eight-year follow-up of pulmonary function and oxygen uptake during exercise in 16-year-old males with cystic fibrosis. Acta Paediatr 1992;81:527-531.
141. Moorcroft AJ, Dodd ME, Webb AK: Exercise testing and prognosis in adult cystic fibrosis. Thorax 1997;52:291-293.
142. Tantisira KG, Systrom DM, Ginns LC: An elevated breathing reserve index at lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2002;165:1629-1633.